Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kyushu University
With
Merck Sharp & Dohme LLC
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Subjects aged 20 years or older.
2. Patients positive for HCV RNA for over 6 months and infected with genotype 1b chronic hepatitis C, including compensated cirrhosis.
3. Patients without co-infection of hepatitis B virus.
4. Patients without co-infection of human immunodeficiency virus
5. Patients with moderate chronic kidney disease (CKD stage 3) (eGFR: 30-59 mL/min/1.73m2). A diagnosis of CKD is only confirmed if repeated eGFR tests for at least 90 days.
You may not be if
1. Patients with decompensated cirrhosis (Child Pugh B and C)
2. Patients with albumin \<3.0 g/dL and platelets \<75,000 /μL
3. Patients with autoimmune hepatitis
4. Constant heavy alcohol drinkers (converted to ethanol ≥60 g/day)
5. Patients who have a history of hypersensitivity to grazoprevir and elbasvir
6. Patients who are pregnant females, or females who may become pregnant, or females who are breastfeeding
7. Patients with heart disease that is hard to control (e.g., very recent cardiac infarction, severe heart failure, unstable arrhythmia)
8. Patients who are under medication with drugs listed as contraindication in a package insert of grazoprevir plus elbasvir treatment
9. Patients judged (by the physician in charge of research) to be inappropriate as subjects for the study for any other reasons.
Clareo Health | A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir
